Tag Archive for: Abecma

Today the agency allowed the use of Bristol-Myers Squibb (BMY.N) and 2seventybio’s cell therapy Abecma in less severely affected patients with a type of blood cancer.

Cancer treatment maker 2seventy bio,  said it will sell all its experimental cell therapies to Regeneron Pharmaceuticals to focus on its only approved product Abecma.

The U.S. health regulator will not meet its Dec. 16 deadline on the use of Bristol Myers Squibb and partner 2seventy bio’s blood cancer therapy in earlier lines of treatment as it plans to seek the advice of independent experts before making a decision, the companies said.

The company will save about $130 million in 2024-25 as it eliminates 176 roles.

Bristol Myers Squibb and 2seventy bio published positive results Friday from a pivotal trial of their B-cell maturation antigen–directed (BCMA) CAR T-cell therapy in multiple myeloma patients who had received two to four prior lines of therapy.

Drugmakers including Pfizer Inc., GlaxoSmithKline PLC, Bristol Myers Squibb, AstraZeneca PLC, and Sanofi SA plan to raise prices in the United States on more than 350 unique drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors.